IHE participates regularly in scientific congresses and meetings. Active participation at such events keeps us in touch with the international frontline of research and helps us identify current debates and work in the area. It also enables us to continually develop our own competence.
IHE is part of a newly established European consortium DO->IT. DO->IT will manage and coordinate the Innovative Medicines Initiative (IMI) comprehensive programme "Big Data for Better Outcomes" (BD4BO). The BD4BO programme aims to improve efficiency in health care, leading to better treatment results and drive development towards value-based pricing and reimbursement models. Leveraging the growing digitization of health care and society at large will help to improve knowledge on the effectiveness of different therapies in clinical practice. The programme is expected to last for at least 5 years.
DO->IT is led by the London School of Economics (LSE), together with Novartis. In total, the consortium has about 30 members, including patient organizations, academia and authorities working side by side with some of the world's leading pharmaceutical companies. Swedish participants include the Dental and Pharmaceutical Benefits Agency (TLV) and IHE.
During the first two years, the consortium will develop the programme strategy and coordinate the various projects within the programme. So far, activities have started on Alzheimer's disease and hematologic diseases, but several additional projects are on track, particularly in prostate cancer. The DO->IT consortium will also identify additional areas where there is currently a lack of real-world evidence and establish common rules for how the programme should handle patients' right to integrity. IHE is expected to take a leading role, particularly regarding the programme strategy.
The BD4BO programme was started in 2015 by IMI. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and is often described as the world's largest public-private partnership. For more information »
For more information about IMI »
Mount Hood Challenge
The Mount Hood Challenge, named after the site of the first meeting in 2000, is a forum for computer modelers of diabetes to discuss and compare models, to assess predictions against data from clinical trials and observational data, and to identify key future developments in the field (including the handling of uncertainty, model validation, and evolving methodology).
In total, there have been 7 Mt. Hood meetings at a variety of sites. IHE staff have been involved in the planning and organization beginning with the fifth Mt. Hood Challenge. The 8th Mt Hood Challenge, 17-18 September 2016, St. Gallen, Switzerland
Since 2007, IHE is participating in a European Commission research project involving organisations from 10 European countries. The purpose of the project, EuroVaQ - European Value of a Quality Adjusted Life Year, is to develop robust methods to determine the monetary value of a quality adjusted life year (QALY) across a number of European Member States. The project aims to gather information and knowledge from all the participating countries.
A major issue in cost effectiveness analysis is that of the value to place on a quality adjusted life year (QALY), commonly used as a measure of health care effectiveness across Europe. This has come to the fore in several European countries, resulting from the creation of national health technology and pharmaceutical assessment agencies. This critical policy issue is reflected in the growing interest across Europe in development of more sound methods to elicit such a value.
To model a value of a QALY two different approaches are taken in this project: firstly through modelling such a value based on values of statistical lives currently used across the participating countries, and also through a population survey to test two methods of deriving a societal willingness-to-pay (WTP) based monetary value of a QALY.
Social economic burden and health-related quality of life in patients with rare diseases in Europe
BURQOL-RD was funded by the European Union in the framework of the Health Programme and it was coordinated by the Fundación Canaria de Investigación y Salud (FUNCIS) in 2010.
The main aim of BURQOL-RD was to develop a disease based model (instrument) to assess the impact of new health policies, interventions and treatments in the field of rare diseases (RDs) by means of quantifying the Economic Burden and Health-Related Quality of Life (HRQOL) for patients and their caregivers, from a macro societal perspective. Besides, this instrument could be used to recognise, improve and update our knowledge of the socioeconomic impact of RDs in the European Union (both the direct and indirect costs), and their self-perceived health outcomes.